Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 18/20 | 0.68 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26915070 | 0.87 | NPBWR1 (0.57) | NPBWR1MCHR1ALDH1A1HTTPKM | |
| SCHEMBL26914994 | 0.86 | NPBWR1 (0.56) | NPBWR1MCHR1PKMPKLR | |
| SCHEMBL14844531 | 0.84 | NPBWR1 (0.84) | NPBWR1MCHR1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2551062 | 0.82 | NPBWR1 (0.77) | NPBWR1MCHR1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL24687649 | 0.81 | NPBWR1 (0.75) | NPBWR1MCHR1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL29841887 | 0.79 | NPBWR1 (0.56) | NPBWR1MCHR1PKMPKLR | |
| SCHEMBL21521514 | 0.77 | NPBWR1 (0.71) | NPBWR1MCHR1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL24640867 | 0.77 | NPBWR1 (0.68) | NPBWR1MCHR1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL29102671 | 0.77 | NPBWR1 (0.68) | NPBWR1MCHR1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL24251307 | 0.76 | NPBWR1 (0.68) | NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-116724044-A | Tri-heterocyclic compound, preparation method and application thereof | 上海湃隆生物科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| WO-2022166749-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海湃隆生物科技有限公司 | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 | NPBWR1 796/4885MCHR1 4541/4885ALDH1A1 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.